Skip to main content
Clinical Trials/JPRN-UMIN000010988
JPRN-UMIN000010988
Completed
Phase 3

The randomized controlled trial of the efficacy of goshajinkigan and lafutidine after mecobalamin administered in breast cancer patients with chemotherapy-induced peripheral neuropathy. - The efficacy of goshajinkigan and lafutidine after mecobalamin administered in breast cancer patients with chemotherapy-induced peripheral neuropathy.

Department of breast and endocrine surgery, Meiwa Hospital0 sites35 target enrollmentJune 18, 2013

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
chemotherapy-induced peripheral neuropathy
Sponsor
Department of breast and endocrine surgery, Meiwa Hospital
Enrollment
35
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
June 18, 2013
End Date
March 31, 2015
Last Updated
2 years ago
Study Type
Interventional
Sex
Female

Investigators

Sponsor
Department of breast and endocrine surgery, Meiwa Hospital

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • 1\)not mecobalamin administered 2\)with severe complications (such as liver failure, renal failure, heart failure) 3\)with history of allergy 4\)alredy adminstered with Goshajinkigan, Mecobalamin or Lafutidine. 5\)with peripheral neuropathy for other cause (such as diabetes) 6\)receiving drugs to influence peripheral neuropathy 7\)doctore's decision not to be registered to this study

Outcomes

Primary Outcomes

Not specified

Similar Trials